Breaking News

Tweet TWEET

Gamma-Dynacare Medical Laboratories Announces Acquisition of Controlling Interest in Impact Genetics

Gamma-Dynacare Medical Laboratories Announces Acquisition of Controlling 
Interest in Impact Genetics 
Investment strengthens genetic testing expertise in Canada 
Website: www.gamma-dynacare.com 
BRAMPTON, ON, Oct. 3, 2013 /CNW/ - Gamma-Dynacare Medical Laboratories 
(Gamma-Dynacare) announced today that it has completed the acquisition of a 
controlling interest in Impact Genetics Inc. (Impact Genetics), a 
Toronto-based laboratory specializing in high-complexity, disease-specific 
genetic testing. 
"We welcome this opportunity to strengthen Gamma-Dynacare's position as a 
leading Canadian reference laboratory," said Naseem Somani, President and 
Chief Executive Officer, Gamma-Dynacare Medical Laboratories. "Experts 
around the world seek out the specialized genetic testing expertise of Impact 
Genetics. This investment brings to Gamma-Dynacare expanded capabilities in 
molecular medicine, oncology and genetic testing for rare diseases that will 
enhance our continued growth in the field of personalized medicine." 
Impact Genetics is recognized by oncologists and geneticists around the world 
as a leader in genetic testing for rare diseases. With a test menu including 
Retinoblastoma RB, Hereditary Hemorrhagic Telangiectasia (HHT), Von 
Hippel-Lindau Syndrome VHL and Gene Copy Number Analysis, Impact Genetics 
serves clients throughout North America, Asia and Europe. New tests for Uveal 
Melanoma and Inherited Leukemia will soon be launched. 
"This exciting partnership will provide Canadians with better genetics 
services and build on local expertise and talent in this rapidly expanding 
market," said Franny Jewett, CEO, Impact Genetics. 
Over the coming months, Impact Genetics' operations will move to 
Gamma-Dynacare's centre of excellence for pathology, immunopathology, genetics 
and pharmacogenomics testing in Bowmanville Ontario, near Toronto. Ms. 
Jewett, Medical Director Dr. Brenda Gallie and the entire Impact Genetics team 
will remain in their respective roles with the company. 
"It was Gamma-Dynacare's commitment to molecular medicine, reputation for 
quality and expertise in high volume laboratory test services that attracted 
us. Our scientific discoveries will have global impact because this 
partnership allows us to grow and deliver on our mission of providing 
cost-effective, high quality genetic testing for rare diseases," explained Dr. 
Gallie, an internationally recognized leader in retinoblastoma genetics, 
biology and clinical care. 
About Impact Genetics Inc. 
Impact Genetics is committed to providing high quality genetic diagnostics for 
rare diseases to as many people as possible. Impact's tests improve the health 
of entire families by: 


    --  identifying members of a family who carry a disease-causing
        mutation;
    --  focusing treatment on relatives at risk; and
    --  eliminating from surveillance relatives who are not at risk.
        Quality: Impact Genetics' tests are equal to or exceed the most
        accurate and sensitive tests available. This is achieved
        through medical and scientific expert oversight, leading edge
        technology, continual test refinement and comprehensive
        reporting.
        Service excellence: Impact Genetics' exceptional service
        supports referring healthcare professionals and payers and
        improves outcomes for patients.
        Expertise: Impact focuses on genetic testing for diseases
        initiated by novel mutations that require a high degree of gene
        and disease-specific knowledge. For each disease, we
        collaborate with genetics, medical, scientific and informatics
        experts, and where consented, provide access to anonymous
        clinical test data for research and publication.

Impact has been providing clinical genetic testing to patients from 25 
countries since 1999 and is the world leader in retinoblastoma genetics.

About Gamma-Dynacare Medical Laboratories

Providing Information. Impacting Lives. Caring for People. By living 
this mission, Gamma-Dynacare Medical Laboratories will achieve its vision of 
becoming the trusted leader in transforming laboratory information and 
services into solutions that improve health, wellness and the Canadian health 
care system.

Gamma-Dynacare is one of Canada's largest and most respected providers of 
laboratory services and solutions, with more than 50 years of experience 
serving Canadians. Headquartered in Brampton, Ontario, Gamma-Dynacare 
operates laboratories in Ontario (Brampton, Bowmanville, London, Ottawa and 
Thunder Bay), Quebec (Saint-Laurent and Laval), Manitoba (Winnipeg) and 
Alberta (Edmonton).

In addition, Gamma-Dynacare operates more than 200 Patient Services Centres in 
Ontario, Quebec, Manitoba, Saskatchewan and Alberta. Gamma-Dynacare's 2,400 
skilled and dedicated employees perform 50 million tests each year, playing a 
key role in the prevention and diagnosis of disease and the treatment of 
patients.



SOURCE  Gamma-Dynacare Medical Laboratories 
Scott Hickey Vice-President, Strategic Planning and Corporate Communications 
Gamma-Dynacare Medical Laboratories (905) 790-3515 or 1-866-790-3515, ext. 
5381 hickeys@gamma-dynacare.com  
Franny Jewett CEO Impact Genetics (647) 478-4902 or 1-877-624-9769 ext. 
100 fjewett@impactgenetics.com   
To view this news release in HTML formatting, please use the following URL: 
http://www.newswire.ca/en/releases/archive/October2013/03/c6935.html 
CO: Gamma-Dynacare Medical Laboratories
ST: Ontario
NI: HEA MTC MNA  
-0- Oct/03/2013 13:51 GMT
 
 
Press spacebar to pause and continue. Press esc to stop.